Barrett's esophagus is defined as the endoscopic finding in the distal esophagus of proximal-appearing columnar-lined esophagus of at least 1-cm length that is confirmed by histology.
It is considered a premalignant metaplastic condition that usually involves the distal esophagus.
It is postulated that exposure of the esophageal epithelium to acid damages the lining resulting in chronic esophagitis and its healing involves metaplastic process.
A single use trasnasal endoscope, named EG Scan, is safe and highly accurate for detecting Barret’s oesophagus, with the sensitivity and specificity being higher than 90 percent, as compared with conventional esophagogastroduodenoscopy, according to a study.
Factors such as Barret’s oesophagus (BE) length, presence of low-grade dysplasia (LGD) and nodularity increase the risk of progression from nondysplastic (ND)BE or LGD to high-grade dysplasia or oesophageal adenocarcinoma, a study has found.
Aspirin may exert a protective effect on the risk of Barrett’s oesophagus (BE) in women, with the effect being evident in regular aspirin users who take higher doses and who have longer duration of exposure, a recent study has found.
Barret’s oesophagus patients do not appear to be at greater risk of osteoporotic fractures compared with the general population, according to a study. Moreover, the use of proton pump inhibitors (PPI) does not contribute to an increased risk regardless of the duration of therapy or dosing strategy.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Gastroenterology - Malaysia digital copy today!
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.